Kura Oncology/$KURA
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Kura Oncology
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.
- Ticker
- $KURA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 260
- Headquarters
- San Diego, United States
- Website
- www.kuraoncology.com
Kura Oncology Metrics
BasicAdvanced
$714M
-
-$3.30
0.53
-
Price and volume
Market cap
$714M
Beta
0.53
52-week high
$13.90
52-week low
$6.75
Average daily volume
2.1M
Financial strength
Current ratio
3.595
Quick ratio
3.427
Long term debt to equity
0.859
Total debt to equity
1.438
Interest coverage (TTM)
-227.12%
Profitability
EBITDA (TTM)
-311.295
Gross margin (TTM)
-227.02%
Net profit margin (TTM)
-369.26%
Operating margin (TTM)
-394.32%
Effective tax rate (TTM)
-0.03%
Revenue per employee (TTM)
$310,000
Management effectiveness
Return on assets (TTM)
-32.15%
Return on equity (TTM)
-224.85%
Valuation
Price to revenue (TTM)
8.703
Price to book
39.75
Price to tangible book (TTM)
39.75
Price to free cash flow (TTM)
-7.745
Free cash flow yield (TTM)
-12.91%
Free cash flow per share (TTM)
-1.003
Growth
Revenue change (TTM)
-23.76%
Earnings per share change (TTM)
32.93%
3-year earnings per share growth (CAGR)
17.77%
10-year earnings per share growth (CAGR)
8.16%
What the Analysts think about Kura Oncology
Analyst ratings (Buy, Hold, Sell) for Kura Oncology stock.
Analyst projections of the future price of Kura Oncology stock.
Bulls say / Bears say
KOMZIFTI’s launch is gaining traction: second-quarter product revenue rose 57% sequentially to $9.1 million, with about 115 new patient starts and a reported majority share of new starts in its market. (Kura Oncology)
Early frontline results support a wider role for ziftomenib: the phase 1b study reported a 96% composite remission rate and 94% 12-month survival in newly diagnosed NPM1-mutated AML. Phase 3 testing is under way to confirm whether those results hold up. (Kura Oncology)
Darlifarnib could give Kura a second growth driver beyond leukaemia: in a kidney-cancer study with cabozantinib, response rates reached 50% and median progression-free survival was 13 months. (Yahoo Finance)
The launch lead is not yet settled: Kura’s majority-share claim conflicts with a rival’s claim of roughly two-thirds of new starts, while treatment duration remains unproven. Flat starts or weak repeat prescriptions would weaken the early revenue case. (Finviz)
Kura remains loss-making and cash is shrinking: its second-quarter net loss was $68.3 million and liquidity fell to $519 million from $667.2 million at year-end. Its expected runway through the 2028 pivotal readout partly relies on anticipated Kyowa Kirin payments. (Kura Oncology)
Darlifarnib’s kidney-cancer combination has a safety hurdle: 58% of patients had grade 3 or worse adverse events, and grade 3 neutropenia occurred in 38%. This could constrain dosing as the programme advances. (Yahoo Finance)
Data summarised monthly by Lightyear AI. Last updated on 5 Nov 2026.
Kura Oncology Financial Performance
Revenues and expenses
Kura Oncology Earnings Performance
Company profitability
Upcoming events
No upcoming events
Kura Oncology News
AllArticlesVideos
Funds containing Kura Oncology
Fund name | Fund size | $KURA weighting |
|---|---|---|
iShares Healthcare Innovation£DRDR | $1.6B | 0.06% |
iShares Healthcare Innovation€2B78 | $1.6B | 0.06% |
iShares Healthcare Innovation$HEAL | $1.6B | 0.06% |
iShares Ageing Population£AGES | $887M | 0.05% |
iShares Ageing Population€AGED | $887M | 0.05% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.